Bio-Rad Laboratories Income Statement (2009-2026) | BIO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	715.90M	747.00M	732.80M	700.10M	691.10M	680.80M	730.30M	676.80M	681.10M	632.10M	681.20M	610.80M	638.50M	649.70M	667.50M	585.40M	651.60M	653.00M	693.20M	592.10M
Cost of Revenue (Quarter)	314.33M	309.61M	334.33M	297.43M	296.07M	308.23M	333.17M	314.43M	318.63M	296.44M	314.81M	284.90M	283.40M	293.80M	325.60M	279.40M	306.30M	309.60M	348.00M	282.70M
Gross Profit (Quarter)	401.10M	436.50M	399.90M	402.60M	395.00M	372.60M	397.10M	362.40M	362.50M	335.70M	366.30M	325.90M	355.10M	355.90M	342.00M	306.00M	345.30M	343.40M	345.20M	309.40M
Operating items
Research & Development (Quarter)	63.39M	64.48M	58.85M	59.53M	64.35M	66.81M	66.21M	74.95M	65.04M	43.53M	63.87M	66.40M	58.90M	91.00M	79.60M	73.50M	60.50M	71.30M	70.30M	62.90M
Selling, General & Administrative (Quarter)	213.43M	216.15M	221.69M	196.69M	207.79M	211.11M	212.20M	225.55M	207.82M	201.20M	207.12M	214.90M	194.70M	200.40M	204.00M	208.80M	207.70M	206.80M	221.00M	212.40M
Operating Expenses (Quarter)	276.82M	280.63M	280.55M	256.23M	272.14M	277.92M	278.41M	300.50M	272.87M	244.73M	271.00M	281.30M	253.60M	291.40M	283.60M	282.30M	268.20M	278.10M	291.30M	275.30M
Operating Income (Quarter)	124.78M	156.80M	117.89M	146.41M	122.89M	94.65M	118.65M	61.91M	89.62M	90.95M	95.32M	44.60M	101.50M	64.50M	58.30M	23.70M	77.10M	65.30M	-118.90M	34.10M
EBIT (Quarter)	124.78M	156.80M	117.89M	146.41M	122.89M	94.65M	118.65M	61.91M	89.62M	90.95M	95.32M	44.60M	101.50M	64.50M	58.30M	23.70M	77.10M	65.30M	-118.90M	34.10M
Non-operating items
Non Operating Investment Income (Quarter)	1,030.69M	4,868.66M		-4545.12M	-1338.19M	-289.00M		-17.52M	-1595.44M	36.42M		422.20M	-2895.40M	792.90M		31.80M	334.40M	-495.30M		-738.20M
Other Non Operating Income (Quarter)	1.76M	-0.60M	10.80M	0.40M	-0.90M	-4.36M	-5190.47M	2.35M	16.49M	20.40M	-80.10M	34.60M	1.70M	17.90M	87.40M	0.50M	-1.10M	1.00M	4.40M	2.40M
Non Operating Income (Quarter)	-0.10M	-0.58M	10.07M	32.60M	6.70M	3.06M	2.33M	50.43M	16.50M	20.40M	19.10M	34.60M	18.20M	17.90M	19.60M	37.20M	16.20M	8.30M	28.60M	24.20M
Net income details
EBT (Quarter)	1,156.80M	5,022.20M	-2027.15M	-4368.00M	-1220.20M	-207.32M	1,091.40M	84.83M	-1500.43M	137.10M	428.40M	491.10M	-2786.30M	861.60M	-908.90M	83.40M	414.00M	-431.10M	929.20M	-689.80M
Tax Provisions (Quarter)	242.66M	1,094.19M	-461.84M	-1000.68M	-295.09M	-44.51M	263.59M	15.87M	-338.18M	30.84M	78.66M	107.20M	-620.80M	208.40M	-193.10M	19.40M	96.20M	-89.20M	209.20M	-162.70M
Profit After Tax (Quarter)	916.80M	3,929.60M	-1572.20M	-3367.30M	-925.10M	-162.80M	827.70M	69.00M	-1162.30M	106.30M	349.70M	383.90M	-2165.50M	653.20M	-715.80M	64.00M	317.80M	-341.90M	720.00M	-527.10M
Net Income - Minority (Quarter)
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)	914.14M	3,928.01M	-1565.31M	-3367.32M	-925.11M	-162.81M	827.81M	68.96M	-1162.25M	106.25M	349.74M	383.90M	-2165.50M	653.20M	-715.80M	64.00M	317.80M	-341.90M	720.00M	-527.10M
Consolidated Net Income (Quarter)	914.14M	3,928.01M	-1565.31M	-3367.32M	-925.11M	-162.81M	827.81M	68.96M	-1162.25M	106.25M	349.74M	383.90M	-2165.50M	653.20M	-715.80M	64.00M	317.80M	-341.90M	720.00M	-527.10M
Income towards Parent Company (Quarter)	914.14M	3,928.01M	-1565.31M	-3367.32M	-925.11M	-162.81M	827.81M	68.96M	-1162.25M	106.25M	349.74M	383.90M	-2165.50M	653.20M	-715.80M	64.00M	317.80M	-341.90M	720.00M	-527.10M
Net Income towards Common Stockholders (Quarter)	914.14M	3,928.01M	-1565.31M	-3367.32M	-925.11M	-162.81M	827.81M	68.96M	-1162.25M	106.25M	349.74M	383.90M	-2165.50M	653.20M	-715.80M	64.00M	317.80M	-341.90M	720.00M	-527.10M
Additional items
EPS (Basic) (Quarter)	30.80	131.80	-52.54	-112.50	-31.05	-5.48	27.89	2.33	-39.59	3.65	12.15	13.46	-76.26	23.37	-25.57	2.29	11.67	-12.70	26.41	-19.55
EPS (Weighted Average and Diluted) (Quarter)	30.41	130.02	-52.54	-112.50	-31.05	-5.48	27.78	2.32	-39.59	3.64	12.14	13.45	-76.26	23.34	-25.57	2.29	11.67	-12.70	26.39	-19.55
Shares Outstanding (Weighted Average) (Quarter)	29.76M	29.81M	29.83M	29.93M	29.86M	29.82M	29.79M	29.60M	29.48M	29.35M	29.21M	28.52M	28.46M	28.29M	28.21M	27.94M	27.23M	26.92M	27.26M	26.96M
Shares Outstanding (Diluted Average) (Quarter)	30.15M	30.22M	30.21M	29.93M	29.79M	29.73M	29.79M	29.75M	29.36M	29.22M	29.21M	28.54M	28.46M	28.29M	28.21M	27.95M	27.59M	27.37M	27.28M	26.96M
EBITDA (Quarter)	124.78M	156.80M	117.89M	146.41M	122.89M	94.65M	118.65M	61.91M	89.62M	90.95M	95.32M	44.60M	101.50M	64.50M	58.30M	23.70M	77.10M	65.30M	-118.90M	34.10M
Interest Expenses (Quarter)	0.36M	0.43M	0.36M	4.05M	10.72M	11.66M	11.67M	12.34M	12.34M	12.40M	12.32M	12.30M	12.30M	12.10M	12.20M	12.00M	12.60M	12.30M	12.10M	12.30M
Tax Rate (Quarter)	20.98%	21.79%	22.78%	22.91%	24.18%	21.47%	24.15%	18.70%	22.54%	22.50%	18.36%	21.83%	22.28%	24.19%	21.25%	23.26%	23.24%	20.69%	22.51%	23.59%

Research Tools

Bio-Rad Laboratories Income Statement (2009-2026) | BIO

Create an account

Sign In

Reset Password